Fig. 2
From: PDZK1 inhibits MRP2-mediated oxaliplatin chemosensitivity in hepatocellular carcinoma
PDZK1 suppresses OXA chemosensitivity of hepatocellular carcinoma. A Western Blot (cropped images) analysis of PDZK1 expression in PDZK1-overexpressed and control HepG2 cells. B Cell viability of OXA treated PDZK1-overexpressed and control HepG2 cells. Repeated measurement ANOVA, * p < 0.05. C Transwell invasion assay of OXA treated PDZK1-overexpressed and control HepG2 cells. Unpaired t-test, ns represents p>0.05, * p < 0.05. D Western Blot (cropped images) analysis of PDZK1 expression of PDZK1 stable overexpression (Huh7-PDZK1-OE) and control (Huh7-PDZK1-NC) cells. E Cell viability and IC50 value of Huh7-PDZK1-NC (left) and Huh7-PDZK1-OE (right) cells treated with OXA concentration gradient for 48 h. F Transwell migration and invasion assay of OXA-treated Huh7-PDZK1-NC and Huh7-PDZK1-OE cells. Unpaired t-test, *** p < 0.001. G Western Blot (cropped images) analysis of PDZK1 expression in siPDZK1 and control HepG2 cells. H Cell viability of OXA treated siPDZK1 and control cells. Repeated measurement ANOVA, *** p < 0.001. I Transwell invasion assay of OXA treated siPDZK1 and control cells. Unpaired t-test, ns represents p>0.05, *** p < 0.001. J Subcutaneous transplantation tumor model detection of Huh7-NC and Huh7-PDZK1 chemotherapy sensitivity to OXA. Two-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001.
